

Inventors: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 2

- Group 1 : Claims 1-3, 4-8 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype A;
- Group 2 : Claims 1, 2, 9-13 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype B;
- Group 3 : Claims 1-3, 14-20 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype C1;
- Group 4 : Claims 1-3, 21-25, and 45-66 (in part), drawn to a substrate for botulinum toxin serotype D;
- Group 5 : Claims 1-3, 26-30 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype E;
- Group 6 : Claims 1-3, 31-35 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype F;
- Group 7 : Claims 1-3, 36-39 and 45-66 (in part), drawn to a substrate for botulinum toxin serotype G;
- Group 8 : Claims 1-3, 40-44 and 45-66 (in part), drawn to a substrate for tetanus toxin;

Inventors: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 3

- Group 9 : Claims 68-70 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype A;
- Group 10 : Claims 68-69, 71 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype B;
- Group 11 : Claims 68-69, 72 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype C1;
- Group 12 : Claims 68-69, 73 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype D;
- Group 13 : Claims 68-69, 74 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype E;
- Group 14 : Claims 68-69, 75 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype G;
- Group 15 : Claims 68-69, 76 and 78-95 (in part), drawn to a method using substrates for botulinum toxin serotype G; and

Inventors: Steward et al.
Serial No.: 09/942,098
Filed: August 28, 2001
Page 4

Group 16 : Claims 68-69, 77 and 78-95 (in part),
drawn to a method using a substrates for
tetanus toxin.

Applicant assumes that claim 67, which was not
mentioned in the Restriction Requirement, is to be grouped with
claims 45 to 66. If this assumption is not correct, the Examiner
is requested to contact the undersigned agent.

Applicant hereby elects without traverse the claims of
Group I (claims 1 to 3, 4 to 8 and 45 to 67 (in part)), drawn to
a BoNT/A clostridial toxin substrate.

III. CONCLUSION

In view of the remarks submitted herein, Applicants
respectfully request that the claims of Group I be examined.

The Examiner is invited to call the undersigned agent
or Cathryn Campbell if there are any questions regarding this
application.

Respectfully submitted,

July 9, 2003
Date

4370 La Jolla Village Drive
Suite 700
San Diego, California 92122

Andrea L. Gashler
Andrea L. Gashler
Registration No.: 41,029
Telephone: (619) 535-9001
Facsimile: (619) 535-8949